The VcR-CVAD Regimen Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma (MCL): First Analysis of E1405-A Phase II Study of VcR-CVAD with Maintenance Rituximab for MCL. 51st Annual Meeting and Exposition of the American-Society-of-Hematology Kahl, B. S., Li, H., Smith, M. R., Gascoyne, R. D., Paietta, E., Advani, R., Horning, S. J. AMER SOC HEMATOLOGY. 2009: 663–63

View details for Web of Science ID 000272725802029